Home
About
Overview
Sharing Data
ORCID
Help
History (2)
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
Nontranscriptional actions of the glucocorticoid receptor.
See All 2 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML.
A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML. Leukemia. 2024 01; 38(1):58-66.
View in:
PubMed
subject areas
Antineoplastic Combined Chemotherapy Protocols
Cytarabine
Daunorubicin
Humans
Idarubicin
Leukemia, Myeloid, Acute
Remission Induction
authors with profiles
Richard A. Larson